PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics.
作者信息
Kargbo Robert B
机构信息
Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.
出版信息
ACS Med Chem Lett. 2020 May 18;11(6):1090-1091. doi: 10.1021/acsmedchemlett.0c00235. eCollection 2020 Jun 11.
Abstract
摘要
相似文献
1
PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics.
ACS Med Chem Lett. 2020 May 18;11(6):1090-1091. doi: 10.1021/acsmedchemlett.0c00235. eCollection 2020 Jun 11.
2
Specific MHC-I Peptides Are Induced Using PROTACs.
Front Immunol. 2018 Nov 22;9:2697. doi: 10.3389/fimmu.2018.02697. eCollection 2018.
3
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
J Hematol Oncol. 2020 May 13;13(1):50. doi: 10.1186/s13045-020-00885-3.
4
Inhibiting TRK Proteins in Clinical Cancer Therapy.
Cancers (Basel). 2018 Apr 4;10(4):105. doi: 10.3390/cancers10040105.
5
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. doi: 10.1002/anie.201507634. Epub 2015 Nov 23.
6
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.
Front Pharmacol. 2021 May 7;12:692574. doi: 10.3389/fphar.2021.692574. eCollection 2021.
7
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
Eur J Med Chem. 2021 Jan 15;210:112981. doi: 10.1016/j.ejmech.2020.112981. Epub 2020 Oct 31.
8
Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Eur J Med Chem. 2019 Jun 15;172:48-61. doi: 10.1016/j.ejmech.2019.03.058. Epub 2019 Mar 26.
9
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
Acta Pharm Sin B. 2020 Oct;10(10):1943-1953. doi: 10.1016/j.apsb.2020.02.010. Epub 2020 Feb 27.
10
Targeting TRK family proteins in cancer.
Pharmacol Ther. 2017 May;173:58-66. doi: 10.1016/j.pharmthera.2017.02.006. Epub 2017 Feb 4.
引用本文的文献
1
FDA-approved kinase inhibitors in PROTAC design, development and synthesis.
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2542357. doi: 10.1080/14756366.2025.2542357. Epub 2025 Aug 12.
2
Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.
Acta Pharm Sin B. 2024 Feb;14(2):517-532. doi: 10.1016/j.apsb.2023.11.010. Epub 2023 Nov 8.
3
E3 ligase ligand optimization of Clinical PROTACs.
Front Chem. 2023 Jan 17;11:1098331. doi: 10.3389/fchem.2023.1098331. eCollection 2023.
4
An overview of PROTACs: a promising drug discovery paradigm.
Mol Biomed. 2022 Dec 20;3(1):46. doi: 10.1186/s43556-022-00112-0.
5
Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation.
ACS Pharmacol Transl Sci. 2022 Sep 5;5(10):849-858. doi: 10.1021/acsptsci.2c00142. eCollection 2022 Oct 14.
本文引用的文献
1
Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Future Oncol. 2020 Mar;16(9):417-425. doi: 10.2217/fon-2019-0647. Epub 2020 Mar 4.
2
Fusions in Central Nervous System Tumors: A Rare, but Worthy Target.
Int J Mol Sci. 2020 Jan 23;21(3):753. doi: 10.3390/ijms21030753.
3
Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors.
Ann Transl Med. 2019 Jul;7(Suppl 3):S155. doi: 10.21037/atm.2019.06.41.
4
Targeting tropomyosin receptor kinase for cancer therapy.
Eur J Med Chem. 2019 Aug 1;175:129-148. doi: 10.1016/j.ejmech.2019.04.053. Epub 2019 Apr 30.
5
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
J Med Chem. 2019 Feb 28;62(4):1731-1760. doi: 10.1021/acs.jmedchem.8b01092. Epub 2018 Sep 19.
Zotero 插件